Cipla FY25 Annual Earnings Summary
4 quarters covered · ₹27,548 Cr revenue · ₹5,274 Cr PAT · 25.8% average EBITDA margin.
Quarter-by-quarter progression
Management promises made during the year
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q2 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q2 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q3 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q4 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q4 FY25Risks flagged during the year
Goa facility received six 483 observations after U.S. FDA reinspection; official classification awaited, which could impact product approvals.
Q2 FY25 · highSupply issues at partner site will reduce Q3 lanreotide sales significantly; recovery depends on partner's production ramp-up.
Q2 FY25 · highGoa facility received Form 483 observations; classification still awaited, which could impact Abraxane launch timeline and other approvals.
Q3 FY25 · highUS FDA issued Form 483 observations at Virgonagar (Bengaluru) and MDI facilities; official classification awaited, potentially delaying product approvals.
Q3 FY25 · highRevlimid revenue is flat sequentially and expected to decline as competition increases; new launches may only partially offset the reduction.
Q4 FY25 · highRevlimid exclusivity ends in FY26, which will compress revenue and margins in the U.S. business.
Q1 FY25 · mediumNew competitors entering the Albuterol inhalation market could lead to price erosion and market share loss, though management notes market expansion.
Q1 FY25 · mediumSupply from partner is constrained, leading to gradual ramp-up for Lanreotide generic; capacity limitations may cap near-term revenue.
Q2 FY25 · mediumBlended US price erosion of ~10% YoY, with potential for further pressure from new competition in Albuterol and other products.
Q2 FY25 · mediumSlow seasonal growth in acute category, especially anti-infectives, impacted India business; recovery dependent on respiratory season.
Q3 FY25 · mediumLanreotide supply issues impacted US revenue; management expects normalization by end of Q4, but full capacity recovery may extend into Q1 FY26.
Q3 FY25 · mediumPotential US tariffs on pharmaceutical imports could impact margins; management noted de-risking via US facilities but awaits policy clarity.
What changed through the year
Q1 FY25 · EBITDA margin guidance of 24.5%-25.5% for FY25
Management reiterated EBITDA margin range of 24.5%-25.5% for the full year, despite strong Q1 performance.
Q1 FY25 · U.S. sustainable quarterly run rate of $235-240 million
Expect U.S. business to settle at $235-240 million per quarter going forward, excluding one-time benefits.
Q1 FY25 · Two peptide launches expected in H2 FY25
Two additional peptide products are expected to launch in Q3 and Q4 of FY25, with two more following in subsequent years.
Q1 FY25 · Advair filing by end of 2024, potential launch in H1 CY2025
ANDA filing for Advair expected by December 2024 or January 2025, with potential launch in first half of calendar 2025.
Q2 FY25 · EBITDA margin guidance maintained at 24.5%-25.5% for FY25
Management reiterated full-year EBITDA margin guidance despite Q2 margin of 26.7%, expecting normalized Q3 and Q4.
Q2 FY25 · Generic Advair launch expected in H1 FY2026
Risking of generic Advair progressing as per expectations; launch targeted for first half of fiscal 2026.
Q2 FY25 · Lanreotide supply issues to resolve by end of Q3, recovery in Q4
Supply challenges expected to be resolved by end of Q3, with sharp recovery in lanreotide franchise from Q4 FY25.
Q2 FY25 · One India to outpace market growth on full-year basis
Management expects India business to revert to growth trajectory with respiratory uptick in Q3 and outpace market growth for the full year.
Q3 FY25 · FY26 top-line growth guidance retained
Management reiterated guidance to grow top line in FY26, with further profitability guidance to be provided after budget finalization.
Q3 FY25 · Generic Advair launch in late H1 FY26
Cipla plans to launch generic Advair from its US facility in late first half of FY26, with de-risking progressing as expected.
Q3 FY25 · Abraxane launch in H2 FY26
Abraxane launch expected from Goa facility post-approval, likely in back end of second half FY26 (Q4 FY26).
Q3 FY25 · FY25 EBITDA margin to exceed guidance
EBITDA for FY25 is trending higher than earlier guidance of 24.5%-25.5%, with Q3 margin at 28% but not sustainable.
Q4 FY25 · FY26 EBITDA margin guidance of 23.5%-24.5%
Management guided EBITDA margin in the range of 23.5%-24.5% for FY26, reflecting confidence despite Revlimid exclusivity loss.
Q4 FY25 · Advair launch expected in FY26
Advair will be commercialized from the U.S. facility, with launch expected in FY26 depending on FDA prioritization.
Q4 FY25 · Two to three peptide launches in FY26
Cipla aims to launch two to three peptide assets in FY26, with one expected to be a large asset.
Q4 FY25 · U.S. revenue run rate of ~$220 million for Q1 FY26
Management indicated U.S. revenue for the next quarter is expected to be around $220 million, factoring in Revlimid compression.